Literature DB >> 88287

Progressive rubella panencephalitis: immunovirological studies and results of isoprinosine therapy.

J S Wolinsky, P C Dau, E Buimovici-Klein, J Mednick, B O Berg, P B Lang, L Z Cooper.   

Abstract

Two patients with progressive rubella panencephalitis, one with and one without stigmata of congenital rubella, were treated for 9 months with isoprinosine and showed continued clinical deterioration. Immunoviorological studies performed before, during and after treatment were unaffected by drug therapy. The virus was recovered on one occasion from the lymphocytes of one of these cases. Neither patient showed any major defects in cellular or humoral immunity. However, the lymphocytes of the patient with stigmata of congenital rubella failed to respond to rubella virus in vitro and had a heat stable, non-dialysable serum inhibitor of in vitro protein A stimulated proliferative responses. Both patients' serum interfered with the production of interferon by normal donor lymphocytes following stimulation with rubella and varicella virus antigen. Increasing serum titres of interferon which did not appear to be lymphoid or immune-specific in origin were found in these two cases.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 88287      PMCID: PMC1537624     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  Cell mediated immunity in experimental rubella infections.

Authors:  R Cappel
Journal:  Arch Virol       Date:  1975       Impact factor: 2.574

2.  Protein A from Staphylococcus aureus-a mitogen for human T lymphocytes and B lymphocytes but not L lymphocytes.

Authors:  T Sakane; I Green
Journal:  J Immunol       Date:  1978-01       Impact factor: 5.422

3.  B cell and T cell lymphopenia in systemic lupus erythematosus.

Authors:  M A Scheinberg; E S Cathcart
Journal:  Cell Immunol       Date:  1974-05       Impact factor: 4.868

4.  Rosette-forming cells, immunologic deficiency diseases and transfer factor.

Authors:  J Wybran; A S Levin; L E Spitler; H H Fudenberg
Journal:  N Engl J Med       Date:  1973-04-05       Impact factor: 91.245

5.  Letter: Non-congenital rubella encephalitis.

Authors:  P Lebon; G Lyon
Journal:  Lancet       Date:  1974-08-24       Impact factor: 79.321

6.  Lymphocyte viraemia in congenital rubella.

Authors:  M J Simons; I Jack
Journal:  Lancet       Date:  1968-11-02       Impact factor: 79.321

7.  Study of the lymphocyte in vitro response to rubella antigen and phytohemagglutinin by a whole blood method.

Authors:  E Buimovici-Klein; T Vesikari; C F Santangelo; L Z Cooper
Journal:  Arch Virol       Date:  1976       Impact factor: 2.574

8.  Lymphocyte stimulation by protein A of Staphylococcus aureus.

Authors:  A Forsgren; A Svedjelund; H Wigzell
Journal:  Eur J Immunol       Date:  1976-03       Impact factor: 5.532

9.  Progressive rubella panencephalitis. Late onset after congenital rubella.

Authors:  J J Townsend; J R Baringer; J S Wolinsky; N Malamud; J P Mednick; H S Panitch; R A Scott; L Oshiro; N E Cremer
Journal:  N Engl J Med       Date:  1975-05-08       Impact factor: 91.245

10.  Chronic progressive panencephalitis due to rubella virus simulating subacute sclerosing panencephalitis.

Authors:  M L Weil; H Itabashi; N E Cremer; L Oshiro; E H Lennette; L Carnay
Journal:  N Engl J Med       Date:  1975-05-08       Impact factor: 91.245

View more
  7 in total

1.  Anti-idiotypic antibodies to rubella virus.

Authors:  A Nath; B Slagle; J S Wolinsky
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

2.  Rubella-specific immune complexes after congenital infection and vaccination.

Authors:  P K Coyle; J S Wolinsky; E Buimovici-Klein; R Moucha; L Z Cooper
Journal:  Infect Immun       Date:  1982-05       Impact factor: 3.441

3.  Rubella-associated arthritis: rescue of rubella virus from peripheral blood lymphocytes two years postvaccination.

Authors:  J K Chantler; D K Ford; A J Tingle
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

4.  A placebo-controlled trial of isoprinosine in patients with multiple sclerosis.

Authors:  N M Milligan; D H Miller; D A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-02       Impact factor: 10.154

Review 5.  Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D M Campoli-Richards; E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-11       Impact factor: 9.546

6.  Virus-specific and autoreactive T cell lines isolated from cerebrospinal fluid of a patient with chronic rubella panencephalitis.

Authors:  R Martin; P Marquardt; S O'Shea; M Borkenstein; H W Kreth
Journal:  J Neuroimmunol       Date:  1989-06       Impact factor: 3.478

7.  Types of immunological failure in the "slow-virus" encephalopathies and multiple sclerosis.

Authors:  J Booss
Journal:  Yale J Biol Med       Date:  1980 Jan-Feb
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.